Biopharma Quarterly Dealmaking Statistics, Q3 2015
A look at financing, M&A and alliance activity July–September 2015
Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.
Register for our free email digests: